Torthaí cuardaigh údar :: APM

1

$Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma$

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma de réir Michel Delforge, Nina Shah, Jesús F. San Miguel, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy Campbell, Nikhil C. Munshi

Foilsithe / Cruthaithe 2021

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
2

$Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial$

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings f... de réir Michel Delforge, Paula Rodríguez‐Otero, Nina Shah, Olga Moshkovich, Julia Braverman, Devender Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy Campbell, Nikhil C. Munshi

Foilsithe / Cruthaithe 2023

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
3

$Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma$

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma de réir Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Abu‐Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z. Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo C. Pasquini

Foilsithe / Cruthaithe 2023

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
4

$Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis$

Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis de réir Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J. Harrison, Amani Kitali, Heather Landau, Abu‐Sayeef Mirza, Pallavi Patwardhan, Muzaffar H. Qazilbash, Saad Z. Usmani, Krina K. Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini

Foilsithe / Cruthaithe 2025

Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in:
5

$Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses$

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses de réir Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús G. Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Paula Rodríguez‐Otero

Foilsithe / Cruthaithe 2024

Faigh an téacs iomlán Faigh an téacs iomlán
Artigo

Cuir le mo chuid Ceanán

Sábháilte in: